Company Description
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases.
Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease.
The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology.
The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system.
Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Nov 11, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 141 |
| CEO | Alfred Sandrock |
Contact Details
Address: 75 Hayden Avenue Lexington, Massachusetts 02421 United States | |
| Phone | 857 259 5340 |
| Website | voyagertherapeutics.com |
Stock Details
| Ticker Symbol | VYGR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001640266 |
| CUSIP Number | 92915B106 |
| ISIN Number | US92915B1061 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Trista Morrison | Chief Corporate Affairs Officer and Chief of Staff to the Chief Executive Officer |
| Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Nathan D. Jorgensen M.B.A., Ph.D. | Chief Financial Officer |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder |
| Dr. Mark A. Kay M.D., Ph.D. | Founder |
| Robin Swartz | Chief Business Officer and Chief Operating Officer |
| Todd Carter Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 21, 2026 | 8-K | Current Report |
| Apr 10, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 2, 2026 | 144 | Filing |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 9, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | 144 | Filing |